|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Barbara_Weber
|
|
gptkbp:collaboratesWith
|
gptkb:Gilead_Sciences
|
|
gptkbp:focusesOn
|
precision medicine
cancer therapeutics
synthetic lethality
targeted oncology
|
|
gptkbp:founded
|
2017
|
|
gptkbp:founder
|
gptkb:Andrew_D._Krivoshik
gptkb:Jose_Baselga
gptkb:Tomasz_S._Nowakowski
gptkb:Alan_D'Andrea
gptkb:Barbara_Weber
|
|
gptkbp:hasCompany
|
true
|
|
gptkbp:headquarters_location
|
gptkb:Boston,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tango Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
2021
|
|
gptkbp:notableInvestment
|
gptkb:EcoR1_Capital
gptkb:Perceptive_Advisors
gptkb:RA_Capital_Management
gptkb:Redmile_Group
gptkb:Vida_Ventures
gptkb:Pfizer
gptkb:Casdin_Capital
gptkb:Third_Rock_Ventures
gptkb:Samsara_BioCapital
gptkb:Boxer_Capital
gptkb:Surveyor_Capital
GV (formerly Google Ventures)
Crossover investors
|
|
gptkbp:numberOfEmployees
|
100-200 (as of 2023)
|
|
gptkbp:pipeline
|
gptkb:TNG260
gptkb:TNG348
gptkb:TNG908
TNG462
|
|
gptkbp:stockSymbol
|
gptkb:TNGX
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.tangotx.com/
|
|
gptkbp:bfsParent
|
gptkb:Alexis_Borisy
gptkb:Alexandria_Venture_Investments
gptkb:Osage_University_Partners
gptkb:Samsara_BioCapital
|
|
gptkbp:bfsLayer
|
6
|